https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-at-the-40th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-at-upcoming-investor-conferences-2021-11-08
https://www.nasdaq.com/press-release/black-diamond-therapeutics-reports-third-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/black-diamond-therapeutics-presents-preclinical-data-on-bdtx-1535-braf-and-fgfr
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-pre-clinical-data-on-bdtx-1535-braf-and-fgfr
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-at-the-2021-cantor-fitzgerald-virtual-global
https://www.nasdaq.com/press-release/black-diamond-therapeutics-and-openeye-scientific-announce-collaboration-to-expand
https://www.nasdaq.com/press-release/black-diamond-therapeutics-reports-second-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/black-diamond-therapeutics-announces-appointment-of-mark-velleca-m.d.-ph.d.-to-board
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-at-upcoming-investor-conferences-2021-08-04
https://www.nasdaq.com/press-release/black-diamond-therapeutics-presents-phase-1-pharmacokinetic-safety-and-preliminary
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-host-webcast-presentation-of-data-from-phase-1-dose
https://www.nasdaq.com/press-release/black-diamond-therapeutics-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-phase-1-bdtx-189-data-in-advanced-solid-tumors
https://www.nasdaq.com/press-release/black-diamond-therapeutics-announces-preclinical-data-presentations-on-bdtx-189-and
https://www.nasdaq.com/press-release/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2020-financial
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-pre-clinical-data-on-bdtx-189-and-bdtx-1535-at
https://www.nasdaq.com/press-release/black-diamond-therapeutics-announces-pre-clinical-data-presentations-on-new-programs
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-at-upcoming-investor-conferences-2021-02-23
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-2021-02
https://www.nasdaq.com/press-release/black-diamond-therapeutics-announces-appointment-of-oncology-clinical-development
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-at-the-j.p.-morgan-39th-annual-healthcare
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual
https://www.nasdaq.com/press-release/black-diamond-therapeutics-provides-update-on-gbm-program-and-presents-pre-clinical
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-at-the-jefferies-2020-virtual-london-healthcare
https://www.nasdaq.com/press-release/black-diamond-therapeutics-reports-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/black-diamond-therapeutics-presents-pre-clinical-data-on-lead-product-candidate-bdtx
https://www.nasdaq.com/press-release/black-diamond-therapeutics-to-present-pre-clinical-data-on-lead-product-candidate
